Unified Investment Management Takes Position in Zoetis Inc. $ZTS

Key Points

• Unified Investment Management has purchased 1,890 shares of Zoetis Inc. worth approximately $295,000 during the 2nd quarter, indicating increasing interest from institutional investors in the company.
• Zoetis reported earnings per share (EPS) of $1.76 for the last quarter, surpassing estimates and showing a 4.2% year-over-year revenue increase, which was $2.46 billion.
• Despite several analysts downgrading Zoetis over recent months, the stock has an average rating of "Moderate Buy" with an expected target price of $200.88, signaling continued analyst interest.

Unified Investment Management bought a new position in Zoetis Inc. (NYSE:ZTS - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,890 shares of the company's stock, valued at approximately $295,000.

Several other hedge funds also recently bought and sold shares of ZTS. Nova Wealth Management Inc. acquired a new position in Zoetis in the 1st quarter worth about $25,000. 1248 Management LLC acquired a new position in Zoetis in the 1st quarter worth about $27,000. Saudi Central Bank acquired a new position in Zoetis in the 1st quarter worth about $29,000. Cornerstone Planning Group LLC increased its position in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after purchasing an additional 88 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after purchasing an additional 120 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock opened at $144.73 on Tuesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The company has a market capitalization of $64.14 billion, a PE ratio of 24.91, a price-to-earnings-growth ratio of 2.34 and a beta of 0.88. Zoetis Inc. has a one year low of $139.70 and a one year high of $197.51. The business has a 50 day simple moving average of $151.03 and a 200 day simple moving average of $156.27.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the previous year, the company posted $1.56 EPS. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ZTS shares. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Argus reiterated a "buy" rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.